Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data

Neurology

Volumn 65, Issue 4, 2005, Pages 633-635

  Sastre Garriga, J ^a   Ingle, G T ^a   Rovaris, M ^b   Tellez N ^c   Jasperse, B ^d   Altmann, D R ^a,e   Benedetti, B ^b   Stevenson, V L ^a   Cercignani, M ^a   Leary, S M ^a   Barkhof, F ^d   Brochet, B ^f   Dousset, V ^f   Filippi, M ^b   Montalban, X ^c   Kalkers, N F ^d   Polman, C H ^d   Rovira, A ^c   Miller, D H ^a   Thompson, Alan J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRAIN ATROPHY; BRAIN SIZE; DISABILITY; DISEASE COURSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE;

EID: 20444477614     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000173061.12776.1f     Document Type: Article

References (10)

1. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004;127:1463-1478.
2. McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 2002;8: 40-51.
3. Sormani MP, Bruzzi P, Comi GC, Filippi M. MRI metrics as surrogate markers for clinical relapse rate in relapsing remitting MS patients. Neurology 2002;58:417-421.
4. Sormani MP, Bruzzi P, Beckmann K, for the European Study Group on Interferon Beta-1b in Secondary Progressive MS. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b. Neurology 2003;60:1462-1466.
5. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain 1997;120:1085-1096.
6. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
7. Ingle GT, Stevenson VL, Miller DH, et al. Two-year follow-up study of primary and transitional progressive multiple sclerosis. Mult Scler 2002;8:108-114.
8. Smith SM, Zhang Y, Jenkinson M. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-489.
9. Cottrell DA, Kremenchutzky M, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999;122:625-639.
10. Ingle GT, Sastre-Garriga J, Miller DH, Thompson AJ. Does inflammation have a role in early PPMS: a longitudinal MRI study. Mult Scler 2003;9:S13.